118 related articles for article (PubMed ID: 9421449)
1. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer.
Amling CL; Blute ML; Bergstralh EJ; Slezak JM; Martin SK; Zincke H
Semin Urol Oncol; 1997 Nov; 15(4):222-9. PubMed ID: 9421449
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
5. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
Fair WR; Aprikian AG; Cohen D; Sogani P; Reuter V
Clin Invest Med; 1993 Dec; 16(6):516-22. PubMed ID: 8013156
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
7. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
8. [The treatment of locally advanced (T3) prostatic carcinoma using radical prostatectomy or radiotherapy. A review].
van den Ouden D; Schröder FH
Tijdschr Gerontol Geriatr; 1998 Apr; 29(2):74-9. PubMed ID: 9615377
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
10. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
11. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
13. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
[TBL] [Abstract][Full Text] [Related]
14. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
Carver BS; Bianco FJ; Scardino PT; Eastham JA
J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
17. [Neoadjuvant endocrine therapy in patients with locally advanced prostate cancer].
Maeda O; Meguro N; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1996 Oct; 42(10):821-7. PubMed ID: 8951482
[TBL] [Abstract][Full Text] [Related]
18. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate.
Amling CL; Leibovich BC; Lerner SE; Bergstralh EJ; Blute ML; Myers RP; Zincke H
Semin Urol Oncol; 1997 Nov; 15(4):215-21. PubMed ID: 9421448
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
[TBL] [Abstract][Full Text] [Related]
20. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer.
Wieder JA; Soloway MS
J Urol; 1998 Aug; 160(2):299-315. PubMed ID: 9679867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
